Department of Vascular Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
The Second Clinical Medical School, Nanchang University, Nanchang, Jianxi, China.
BMJ Open. 2022 Dec 9;12(12):e066903. doi: 10.1136/bmjopen-2022-066903.
The revascularisation strategy for lower limb atherosclerosis obliterans (ASO) remains controversial. In this meta-analysis, we will summarise existing evidence to compare the long-term and short-term outcomes between endovascular revascularisation and open revascularisation for patients with ASO.
Relevant randomised controlled trials (RCTs) and cohort studies are included from the following databases: MEDLINE/PubMed, Embase and the Cochrane Library. The last search time is 1 August 2022. Two reviewers will independently identify RCTs and cohort studies according to eligibility and exclusion criteria. The risk of bias of included cohort studies, and RCTs are assessed with the Newcastle-Ottawa Scale, Methodological Index of Non-randomized Studies and Cochrane Collaboration's tool, respectively. The primary outcomes include overall survival, amputation-free survival and 30-day mortality. TSA Beta Software V.0.9.5.10 is used to perform the trial sequential analysis for primary outcomes. The Grades of Recommendations, Assessment, Development and Evaluation (GRADE) tool will be used to assess the level of evidence for outcome from RCTs. Stata V.17.0 software is used to pool primary outcomes.
This study will be disseminated through peer-reviewed journals or conference reports. No ethical approval requirements are required because the results presented in this study are conducted based on published data.
CRD42022359591.
下肢动脉硬化闭塞症(ASO)的血运重建策略仍存在争议。在这项荟萃分析中,我们将总结现有证据,比较腔内血管重建与开放血管重建治疗 ASO 患者的长期和短期结局。
从以下数据库中纳入相关的随机对照试验(RCT)和队列研究:MEDLINE/PubMed、Embase 和 Cochrane 图书馆。最后一次检索时间为 2022 年 8 月 1 日。两名评审员将根据纳入和排除标准独立识别 RCT 和队列研究。纳入的队列研究和 RCT 的偏倚风险分别使用纽卡斯尔-渥太华量表、非随机研究方法学指数和 Cochrane 协作工具进行评估。主要结局包括总生存率、免于截肢生存率和 30 天死亡率。使用 TSA Beta 软件 V.0.9.5.10 对主要结局进行试验序贯分析。将使用推荐、评估、开发和评估分级工具(GRADE)评估来自 RCT 的结局的证据水平。使用 Stata V.17.0 软件对主要结局进行汇总。
本研究将通过同行评议期刊或会议报告进行传播。由于本研究中呈现的结果是基于已发表的数据进行的,因此不需要伦理批准。
PROSPERO 注册号:CRD42022359591。